-
Mashup Score: 26
European Journal of Neurology is the official neurology journal of the European Academy of Neurology covering clinical and basic research in neurology.
Source: onlinelibrary.wiley.comCategories: General Medicine News, NeurologyTweet
-
Mashup Score: 2Amylyx to pull ALS drug from market, cut 70% of staff - 10 day(s) ago
Amylyx Pharmaceuticals will take its ALS drug off the market in the U.S. and Canada, ending a multi-year saga for patients with the disease.
Source: www.statnews.comCategories: General Medicine News, General NewsTweet
-
Mashup Score: 3
This cross-sectional study characterizes the use of and rationale for crowdsourced fundraising by patients with neurological illnesses and their family members.
Source: jamanetwork.comCategories: General Medicine News, NeurologyTweet
-
Mashup Score: 2Failure of ALS drug puts a spotlight on controversial FDA approvals - 1 month(s) ago
A large clinical trial found that Amylyx Pharmaceuticals’ drug to treat ALS doesn’t work, raising questions about the FDA’s process for approving it.
Source: www.washingtonpost.comCategories: General Medicine News, General HCPsTweet
-
Mashup Score: 5Innovative Approaches to Catalyze Preclinical and Clinical Research on Amyotrophic Lateral Sclerosis (ALS) and Related Disorders - 2 month(s) ago
Amyotrophic lateral sclerosis (ALS) stands as a significant neurodegenerative disease within a clinical and pathophysiological continuum with other motor neuron diseases and frontotemporal dementia (FTD). ALS leads to progressive upper and lower motor neuron degeneration, resulting in muscle weakness, paralysis, and ultimately, death within 2 to 5 years after the initial diagnosis. Despite its classification as a rare disease, the socioeconomic burden of ALS is substantial, further compounded by a rising incidence primarily attributed to the aging global population. The urgent need for accelerated research is evident, as enhancing our understanding of ALS holds the promise of unraveling broader insights into neurodegenerative processes. Accelerated research not only offers the potential for improved diagnosis tools and therapeutic intervention but also serves as a vital step toward alleviating the immense emotional, financial, and societal strains imposed by ALS and its related disorde
Source: www.frontiersin.orgCategories: General Medicine News, NeurologyTweet
-
Mashup Score: 43Biogen’s QALSODY® (tofersen), the First Therapy to Treat Rare, Genetic Form of ALS, Received Positive Opinion from CHMP | Biogen - 2 month(s) ago
The Investor Relations website contains information about Biogen’s business for stockholders, potential investors, and financial analysts.
Source: investors.biogen.comCategories: General Medicine News, PayerTweet-
We’ve received a positive opinion from the European Medicine Agency’s Committee for Medicinal Products for Human Use (CHMP) for our treatment for amyotrophic lateral sclerosis (#ALS) in adults who have a specific gene mutation. Learn more about this news: https://t.co/BMl83MOB1e https://t.co/U2enSmz3Nb
-
-
Mashup Score: 0How ALS Can Impact Your Diet And Nutritional Needs - 2 month(s) ago
People with ALS need to eat a nutritious diet and get plenty of calories. But physical challenges of the disease sometimes make that difficult.
Source: www.henryford.comCategories: General Medicine News, General HCPsTweet
-
Mashup Score: 27
Researchers at Case Western Reserve University School of Medicine have discovered why a gene, when mutated, is a common cause of two debilitating brain diseases: Amyotrophic lateral sclerosis (ALS) and …
Source: medicalxpress.comCategories: General Medicine News, General HCPsTweet
-
Mashup Score: 3FDA Denies Accelerated Approval for ALS Drug - 4 month(s) ago
The FDA has rejected Clene Nanomedicine’s application for accelerated approval for the experimental drug ALS drug, CNM-Au8, citing insufficient evidence.
Source: www.medscape.comCategories: General Medicine News, General HCPsTweet
-
Mashup Score: 9Incorporating Genetic Testing Into the Care of Patients with ALS/FTD - 4 month(s) ago
Dr. Gordon Smith talks with Laynie Dratch about integrating genetic testing into patient care for persons with Amyotrophic lateral sclerosis (ALS) and frontotemporal degeneration (FTD) spectrum disorders. Read the related article in . Disclosures can be found at Neurology.org
Source: directory.libsyn.comCategories: General Medicine News, NeurologyTweet-
Neurology Podcast: Dr. Gordon Smith & Laynie Dratch discuss integrating genetic testing into patient care for persons with #ALS & frontotemporal degeneration spectrum disorders. Listen now: https://t.co/0Ha5eOhHs2 Article: https://t.co/lwMQNUu3dB @gordonsmithMD @LayniedratchC https://t.co/yqShCXTVfN
-
➡️ The first EAN guideline on #ALS published in collaboration with @euro_nmd 🤝 It addresses pivotal aspects of ALS management, spanning from pharmacotherapies to non-pharmacological interventions, holistic care, and psychological support. 🔗 https://t.co/8bjPdX2AzJ https://t.co/3n84eM02C1